SMS Pharmaceuticals has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its API facility situated at Kandivalasa, Andhra Pradesh. The USFDA had inspected the said facility during the period January 13, 2020 to January 17, 2020. This facility predominantly caters regulated markets including USA.
SMS Pharmaceuticals is a global player in API manufacturing having strong research and manufacturing team supported by state of art facilities.